{"name":"Guangdong Hengrui Pharmaceutical Co., Ltd","slug":"guangdong-hengrui-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"guangdonghengrui.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"cardiovascular","drugs":[{"name":"HRS-2261 oral tablet","genericName":"HRS-2261 oral tablet","slug":"hrs-2261-oral-tablet","indication":"Other","status":"phase_2"},{"name":"HRS-9813 capsules","genericName":"HRS-9813 capsules","slug":"hrs-9813-capsules","indication":"Other","status":"phase_2"},{"name":"Moxifloxacin Hydrochloride Tablets","genericName":"Moxifloxacin Hydrochloride Tablets","slug":"moxifloxacin-hydrochloride-tablets","indication":"Other","status":"marketed"},{"name":"SHR-1139 Injections","genericName":"SHR-1139 Injections","slug":"shr-1139-injections","indication":"Other","status":"phase_1"},{"name":"SHR-1819","genericName":"SHR-1819","slug":"shr-1819","indication":"Unknown","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"SHR-1905 Injection","genericName":"SHR-1905 Injection","slug":"shr-1905-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"HR-1703","genericName":"HR-1703","slug":"hr-1703","indication":"Cancer (specific indication under phase 3 evaluation not publicly detailed)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Budesonide inhalant","genericName":"Budesonide inhalant","slug":"budesonide-inhalant","indication":"Asthma","status":"phase_2"}]}],"pipeline":[{"name":"SHR-1905 Injection","genericName":"SHR-1905 Injection","slug":"shr-1905-injection","phase":"phase_3","mechanism":"SHR-1905 Injection is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"HR-1703","genericName":"HR-1703","slug":"hr-1703","phase":"phase_3","mechanism":"HR-1703 is a tyrosine kinase inhibitor that targets specific oncogenic pathways to inhibit tumor cell growth and proliferation.","indications":["Cancer (specific indication under phase 3 evaluation not publicly detailed)"],"catalyst":""},{"name":"Budesonide inhalant","genericName":"Budesonide inhalant","slug":"budesonide-inhalant","phase":"phase_2","mechanism":"Glucocorticoid receptor agonist","indications":["Asthma","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"HRS-2261 oral tablet","genericName":"HRS-2261 oral tablet","slug":"hrs-2261-oral-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HRS-9813 capsules","genericName":"HRS-9813 capsules","slug":"hrs-9813-capsules","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Moxifloxacin Hydrochloride Tablets","genericName":"Moxifloxacin Hydrochloride Tablets","slug":"moxifloxacin-hydrochloride-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR-1139 Injections","genericName":"SHR-1139 Injections","slug":"shr-1139-injections","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SHR-1819","genericName":"SHR-1819","slug":"shr-1819","phase":"phase_3","mechanism":"SHR-1819 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxPUV9KRVY2dUNwb1pWWnMzaVllbFdrVlhRYkVoczdySGxDc3VSWU0zTTZBSGxsU21sUk53RldoTHV3V1V5S0RZSUxiTVBjbDlvdml3SEdFTUZ5bXZtNGx4Qlc1QTBaZm9XNmJoZDlaTWZIaGtuOUxMcGd6VnVwSGItejFKVmY2R0hFNkM5NlBWTFFlNmFKUE42dVZHeGI0SkpUckRMcHhhMlBvZGRvQlZwWGxtMVEzZlBlcGtEX2JwRk5NcVgwUEVNVFdaTXhSQzhXdlhJRm15c0hOZmpFZ0RYWDJ6b3h4NzBlU3pRTVZ4QW51enZnSXJsVVdQOHVOZw?oc=5","date":"2026-03-30","type":"trial","source":"Barchart.com","summary":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com","headline":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | Del","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOUWgzamdSaVNlOE1TclRTME9HMDlBejFGeXloNFIzOGx2RjN5ekM4MUR1TUhMMmIzdThYZXdRLUpmYldMRnhVMGJZVF9sLUN0NVlJTW5sQTZ6WEhvN2M3dzhaMW11ZEYwdVRhWlZBWFZKZEJBN2dkOWJvVFVFdGtWRmpwSnZpdWRVUVZoZHkxa2dXejFnM1QzMQ?oc=5","date":"2026-03-30","type":"trial","source":"openPR.com","summary":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+ - openPR.com","headline":"IgA Nephropathy Clinical Trial Pipeline Gains Momentum: 25+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPd2p4RHowNHR3Y3VRTVJRLXE4VnhTN2hZZFBBUGV4RjFsUXp0UlZXQ3d4V2hyM2xFM1FEeWx2Z1FaTWVBV2k5SjVneGVGbVg3cFowMzlwRklPMDZSS01pTWJiQUE5TkRqcUN5emdzSjdXUnFwZlB1ZG80cllvdGpUMTBYenRWN0EtV1VWUUlnbDV6VVdBTlNWcg?oc=5","date":"2026-02-16","type":"pipeline","source":"Financial Times","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight – Company Announcement - FT.com - Financial Times","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOb2FpNnlvQ2NMX0ZSTnZkdGtFUXhFUzhyRXA4SjJQcF9uOHZRaWJDZ1hDUnZ0T0pLWmthYWRmM2NGTVNDZkFOQnZPbFlhY0lNUnJmNkpnYll3eERNOW8wVS1VMFV2QnE5bWMzZDBFcGduUUpqaDBpZGtSNlE1SDVDRTMxNENyMFJud3F0S3pyUi1rMHZhZ1JhUHNtc1VScWZoZkszc0lMYVFOaWhpUk5QMVhtbl92VU9WWlJnR2VwSnp5elhiV1hENHVXV0FpemhUa29jd0JxUGJqWnVFcTZ2dnAxWDQ4LTN4T3pyZ0xIcWtJdFk3dFVqaEp2cng2b0lSOTd0YTVQNGFXMzZteTA0N3VpbDg0U3dDT2J2QVliNGdPUldNa0Zndi1mRzZ3a3h1dHc?oc=5","date":"2026-02-09","type":"trial","source":"GlobeNewswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPandkMnQwNEl6TFNNWFJPMFF6Z3c4MlFzbEZKUnQwbnpUYm91eFQtSGVYMDN1MS1xMXJLdGpWckIweGM1bEl0S0ZQRXU4UkY2VTFrWERkNjBYN1VrcjkzVGMxbHBmWV9QZ2NOZW5pUE42LVlRX0Jpa0xrT2FCLWllU1BCVV8wSmd6ZzdnZmJuNlU?oc=5","date":"2025-07-28","type":"pipeline","source":"GSK","summary":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology - GSK","headline":"GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflam","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOb3ZPVG82bTJTam8tQVFEeG04NTFoMEt6Y0Q0YS04VmhJSjNNMS1pQ003TU03djh3Ull1RnFSbERacjB1UC04MlVrRVFUNExwYVRyV3MzVy1qeThNdDBFd2lTckRaZW5zQXlrNVFYX0x3aTlJb0kybkhVb0lmZnprczV1b0sxOXhiVjh4bnpLYWpsWGhWSGVVMXoxWXQ5OHBXR1Bxc1Q0ME5MRDl4TEhvRVlTRzlqMzdyeHI1M2d3TUU1MVNUTEFieXo0b09OMVRjZ2lxWjAtY1FCRHhfMjNOc2ZjZTJJZHlD?oc=5","date":"2025-05-27","type":"pipeline","source":"PR Newswire","summary":"FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - PR Newswire","headline":"FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNd0dqczdycWQwNG9vQ1BHYUxmSkRCNUdCeVUwV3JvOGNLMFppR3Z0MlBCRW5kMXN0a3ZhUmVVWUVEXzV5czV0dF9yOHU3WjVCTjI3bFdnSWdYZ2V0SXp1VnNoYzRqRnRIZlJVUGNlMWtjMXF1eXhveng0c2ZfbTZfRG9ub1dJcUFpN3ZnXy1zT1p2RzZJRVJzY3owb01DOUVjaDJNczMxVHI4ajNTV001TjhNd0dYcmhPLWFwZEJYak9YcTRnRzJwcE1TMXpkQ0N2NlV1STYtS2R4OGpjNTNhc3lpMVpFWkJaMkczRmI3U2M4dlJ2MC1sSWJaNkk?oc=5","date":"2025-04-28","type":"regulatory","source":"PR Newswire","summary":"Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsight - PR Newswire","headline":"Novartis' VANRAFIA Approval Disrupts IgA Nephropathy Market, Paving Way for New Therapeutic Paradigm | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxPODR6a0JUUjQ2d3pHa2c0M3gtN2ZRMDVGandaRFJha3VIMjg3OEdjWTRZTk1uMlV4Z3ktQUhXZGgxNW9oYmRPQ29NSlpwYklHenlyOElhTnhHTENKZldhZ1JiZ3RWU19CLW5vRUVGWEpneEs4dGY5V1gxRnhHanA2Ni1qQno5SnkyZG40dWxyYWVzVFM4Z2hKaHJqTlg2OEkzTnhMd0hveW5vdEhiRENMVEFxTlVtV1ZwejdjVHhnVlYtR1lhbDVuRzU3YlVETDR3bjhhZm40LWVNcUpKQVdpY2FHZl9JTWQ2VDVRR19KdjFVd1o5RUQzOERDMkZQcEpLWTNwZVJtcjgzR2ppYUJRS01kMnUxOUpLSDlwWFVHT19EaVZDSFhaS2F5cHpNa0MwZjcwVXY1X0dSejgwNUE?oc=5","date":"2025-01-28","type":"trial","source":"GlobeNewswire","summary":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust - GlobeNewswire","headline":"Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQRE0tVHFDTkFjR0pnOEVHY2RxaEFtc3Nna2piVk9FZEg3VjhhOTJSb2FvWGpRdFhJRlFvNVdOV3FfYkJTNGVaSEVGbVpPWjh3REFta3NxM2tSckNkX3dBNVFNWTNUeHdtcVRtdDc0bTMzMVNlTHF6MnNDTUFDcWMxV3dzYmNJbWxUbDJSeGhFdC1wMnU5bG9hZ1h5MDRHM0tWS09WM0xZWkkzUXpOZlNEc25QVmlRNndvZExKZjV0VWFBVlNPTXM1SUJ3em11VzByRUhndk1wRE1ILWVMOUxjXzBXYw?oc=5","date":"2024-09-09","type":"pipeline","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Treatment Drug Market to Increase 2 Folds by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxNVGhpZEFiUzhvRU5fTEFRVm51dXgyT1E2WDVDZ1UxYTJQdi1UV0w4eVhwSGN4Z2wyUk1nUmdSbGZXcGpzb2RzNTNwNWpTTHZiSUJ2ZFlyMUFxMzFXcDNEZTNnd1k0ZkRTVW11UW01SEJval8wc3RaQmJ4UGJYeFAtOXBQcmxSMWYxX3BEejViZEQ0NU5sdldoNWlCVnRpWEVUZVZ5Mm5ScXdtbGVXR2JmSVhia091d1QyRDZ4UXE2cHlNMXpJaUtKX3FYZDB5ZkZfT3k2dFREMzBRdnlWTnNmOFItYy16VjFVMUNhYUFvMlZpbnBzeUdPWHN2R1YxbEwzU1JlaDhKSldqTWs?oc=5","date":"2024-04-03","type":"pipeline","source":"PR Newswire","summary":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight - PR Newswire","headline":"Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQWHNuMmYyU0dYeFRna1RXMU02ck5fSklQZllyVFpBREZXNTRGOHJDejZGcGx4RzBFQzhXeDlpalAyOE8xWTlyTmZVUDAyZkhPV2xoNTZlRkRwOHBhUk14VnBOcEhQN3ZOaDdkb3lJZEdsaVRjWk9mS0tDRGU0VDRyQ0JYX0FlSHh5RjFaeWpab0hiNkwwZVk5NHhPNndOTGFPcWRpRjZJUllGVklqNEtZWnZGNVJidWJQbHA5SzYxRmJPT3JSdDZhZ0hKRjJFRmNUek9WUnU4R3NSOWt4bDhWTUI4RzB5WWYxXzRHa3RhbDU2a3UxY3RXYlBLbHNlLXU3bnNwazZEbS15MXFSdEVDaE5ZU0pfb0N2YXB0eWRTN0dQb3lzTTdaek5EMEFGaDVheng3ZFJkYw?oc=5","date":"2023-05-25","type":"trial","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPSHlGT3NMSGswR0szNG5vd2Y0RWZtUi1HTFpKcGJfdVJWY3JNN2lvTDJYd0VCVWhhNGF4UGUwYVktWG9naDlCdWRhQkpXekFNOXlZUms1bzB6Xy1IbE5FMF91UFZ3ZERfNWJGa09ZMmRSTmluVHMyT3ZtUkJ5RnhiT2tNQV9ubkVYN3JmR01oSQ?oc=5","date":"2022-12-14","type":"trial","source":"Yahoo Finance","summary":"IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsight - Yahoo Finance","headline":"IgA Nephropathy Clinical Trials Pipeline Analysis: 30+ Companies are Working to Improve the Treatment Space | DelveInsig","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":3,"phase_2":3,"marketed":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}